PDE5 inhibitors enhance celecoxib killing in multiple tumor types

Journal of Cellular Physiology

Volumn 230, Issue 5, 2015, Pages 1115-1127

  Booth, Laurence ^a   Roberts, Jane L ^a   Cruickshanks, Nichola ^a   Tavallai, Seyedmehrad ^a   Webb, Timothy ^a   Samuel, Peter ^a   Conley, Adam ^b   Binion, Brittany ^a   Young, Harold F ^b   Poklepovic, Andrew ^b   Spiegel, Sarah ^a   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOPHAGY PROTEIN 5; BECLIN 1; CELECOXIB; FAS ANTIGEN; FINGOLIMOD; MAMMALIAN TARGET OF RAPAMYCIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHOSPHODIESTERASE V; SILDENAFIL; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; BREAST CARCINOMA; CELL KILLING; CONTROLLED STUDY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; FEMALE; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; DRUG EFFECTS; EXPERIMENTAL MAMMARY NEOPLASM; NEOPLASM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; AUTOPHAGY; CELECOXIB; CELL LINE, TUMOR; DRUG SYNERGISM; ENDOPLASMIC RETICULUM STRESS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, NUDE; NEOPLASMS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; PYRAZOLES; SIGNAL TRANSDUCTION; SILDENAFIL CITRATE; SULFONAMIDES;

EID: 84921695231     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24843     Document Type: Article

References (71)

1. Bastos-Pereira AL, Lugarini D, Oliveira-Christoff Ad, Ávila TV, Teixeira S, Pires Ado, Muscará MN, Cadena SM, Donatti L, Cristina da Silva, de Assis H, Acco A. 2010. Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism. Cancer Chemother Pharmacol 65:267-276.
2. Benavides GA, Liang Q, Dodson M, Darley-Usmar V, Zhang J. 2013. Inhibition of autophagy and glycolysis by nitric oxide during hypoxia-reoxygenation impairs cellular bioenergetics and promotes cell death in primary neurons. Free Radic Biol Med 65:1215-1228.
3. Bruzziches R, Francomano D, Gareri P, Lenzi A, Aversa A. 2013. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother 14:1333-1344.
4. Booth L, Cazanave SC, Hamed HA, Yacoub A, Ogretmen B, Chen CS, Grant S, Dent P. 2012. OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing. Cancer Biol Ther 13:224-236.
5. Booth L, Roberts JL, Cruickshanks N, Conley A, Durrant DE, Das A, Fisher PB, Kukreja RC, Grant S, Poklepovic A, Dent P. 2014. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Mol Pharmacol 85:408-419.
6. Carón RW, Yacoub A, Li M, Zhu X, Mitchell C, Hong Y, Hawkins W, Sasazuki T, Shirasawa S, Kozikowski AP, Dennis PA, Hagan MP, Grant S, Dent P. 2005. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther 4:257-270.
7. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. 2002. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci USA 99:13926-13931.
8. Chen S, Cao W, Yue P, Hao C, Khuri FR, Sun SY. 2011. Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3. Cancer Res 71:6270-6281.
9. Chen ST, Thomas S, Gaffney KJ, Louie SG, Petasis NA, Schönthal AH. 2010. Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2. Leuk Res 34:250-253.
10. Choi DE, Jeong JY, Lim BJ, Chung S, Chang YK, Lee SJ, Na KR, Kim SY, Shin YT, Lee KW. 2009. Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. Am J Physiol Renal Physiol 297:F362-F370.
11. Chuang HC, Kardosh A, Gaffney KJ, Petasis NA, Schönthal AH. 2008. COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer 7:38.
12. Cremesti A, Paris F, Grassmé H, Holler N, Tschopp J, Fuks Z, Gulbins E, Kolesnick R. 2001. Ceramide enables fas to cap and kill. J Biol Chem 276:23954-23961.
13. Cruickshanks N, Hamed HA, Booth L, Tavallai S, Syed J, Sajithlal GB, Grant S, Poklepovic A, Dent P. 2013. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer Biol Ther 14:982-996.
14. Das A, Durrant D, Mitchell C, Mayton E, Hoke NN, Salloum FN, Park MA, Qureshi I, Lee R, Dent P, Kukreja RC. 2010. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci USA 107:18202-18207.
15. Das A, Xi L, Kukreja RC. 2008. Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 283:29572-29585.
16. Eberle A, Reinehr R, Becker S, Keitel V, Häussinger D. 2007. CD95 tyrosine phosphorylation is required for CD95 oligomerization. Apoptosis 12:719-729.
17. Florio T, Arena S, Pattarozzi A, Thellung S, Corsaro A, Villa V, Massa A, Diana F, Spoto G, Forcella S, Damonte G, Filocamo M, Benatti U, Schettini G. 2003. Basic fibroblast growth factor activates endothelial nitric-oxide synthase in CHO-K1 cells via the activation of ceramide synthesis. Mol Pharmacol 63:297-310.
18. Flower RJ. 2003. The development of COX2 inhibitors. Nat Rev Drug Discov 2:179-191.
19. Formelli F, Clerici M, Campa T, Di Mauro M, Magni A, Mascotti G, Moglia D, De Palo G, Costa A, Veronesi U. 1993. Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 11:2036-2042.
20. Francis SH, Busch JL, Corbin JD, Sibley D. 2010. CGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 62:525-563.
21. Gandelman M, Levy M, Cassina P, Barbeito L, Beckman JS. 2013. P2×7 receptor-induced death of motor neurons by a peroxynitrite/FAS-dependent pathway. J Neurochem 126:382-388.
22. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD. 2005. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7:164-176.
23. González R, Ferrín G, Aguilar-Melero P, Ranchal I, Linares CI, Bello RI, De la Mata M, Gogvadze V, Bárcena JA, Alamo JM, Orrenius S, Padillo FJ, Zhivotovsky B, Muntané J. 2013. Targeting hepatoma using nitric oxide donor strategies. Antioxid Redox Signal 18:491-506.
24. Grösch S, Tegeder I, Niederberger E, Bräutigam L, Geisslinger G. 2001. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15:2742-2744.
25. Hamed HA, Yamaguchi Y, Fisher PB, Grant S, Dent P. 2013. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells. J Cell Physiol 228:1996-2005.
26. Hayden MA, Lange PA, Nakayama DK. 2001. Nitric oxide and cyclic guanosine monophosphate stimulate apoptosis via activation of the Fas-FasL pathway. J Surg Res 101:183-189.
27. Holliday MW, Jr, Cox SB, Kang MH, Maurer BJ. 2013. C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines. PLoS ONE 8:e74768.
28. Hsieh PS, Tsai HC, Kuo CH, Chan JY, Shyu JF, Cheng WT, Liu TT. 2008. Selective COX2 inhibition improves whole body and muscular insulin resistance in fructose-fed rats. Eur J Clin Invest 38:812-819.
29. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. 2000. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397-11403.
30. Huang KH, Kuo KL, Ho IL, Chang HC, Chuang YT, Lin WC, Lee PY, Chang SC, Chiang CK, Pu YS, Chou CT, Hsu CH, Liu SH. 2013. Celecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells. PLoS ONE 8:e82034.
31. Johnson AJ, Song X, Hsu A, Chen C. 2001. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv Enzyme Regul 41:221-235.
32. Kardosh A, Golden EB, Pyrko P, Uddin J, Hofman FM, Chen TC, Louie SG, Petasis NA, Schönthal AH. 2008. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2, 5-dimethyl-celecoxib. Cancer Res 68:843-851.
33. Kern MA, Haugg AM, Koch AF, Schilling T, Breuhahn K, Walczak H, Fleischer B, Trautwein C, Michalski C, Schulze-Bergkamen H, Friess H, Stremmel W, Krammer PH, Schirmacher P, Müller M. 2006. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 66:7059-7066.
34. Kim B, Giardiello FM. 2011. Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol 25:607-622.
35. Komalavilas P, Shah PK, Jo H, Lincoln TM. 1999. Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells. J Biol Chem 274:34301-34309.
36. Kots AY, Bian K, Murad F. 2011. Nitric oxide and cyclic GMP signaling pathway as a focus for drug development. Curr Med Chem 18:3299-3305.
37. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. 2004. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 96:1769-1780.
38. Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, Tashkin DP, Goodglick L, Holmes EC, Cameron RB, Dubinett SM, Elashoff R, Szabo E, Elashoff D. 2011. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) 4:984-993.
39. Nandakishore R, Ravikiran Y, Rajapranathi M. 2014. Selective Cyclooxygenase Inhibitors: Current Status. Curr Drug Discov Technol 11:127-132.
40. Nichols DJ, Muirhead GJ, Harness JA. 2002. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br. J. Clin. Pharmacol 53:5S-12S.
41. Oh YT, Liu X, Yue P, Kang S, Chen J, Taunton J, Khuri FR, Sun SY. 2010. ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1. J Biol Chem 285:41310-41319.
42. Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Häussinger D, Reinehr R, Larner A, Spiegel S, Fisher PB, Voelkel-Johnson C, Ogretmen B, Grant S, Dent P. 2010. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2 +)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res 70:6313-6324.
43. Park MA, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan MP, Calderwood SK, Sherman MY, Koumenis C, Spiegel S, Chen CS, Graf M, Curiel DT, Fisher PB, Grant S, Dent P. 2008. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol 73:1168-1184.
44. Pilane CM, LaBelle EF. 2004. NO induced apoptosis of vascular smooth muscle cells accompanied by ceramide increase. J Cell Physiol 199:310-315.
45. Piplani H, Rana C, Vaish V, Vaiphei K, Sanyal SN. 2013. Dolastatin, along with Celecoxib, stimulates apoptosis by a mechanism involving oxidative stress, membrane potential change and PI3-K/AKT pathway down regulation. Biochim Biophys Acta 1830:5142-5156.
46. Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, Chow RH, Uddin J, Petasis NA, Mircheff AK, Farley RA, Louie SG, Chen TC, Schönthal AH. 2007. Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2, 5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol Cancer Ther 6:1262-1275.
47. Rabkin SW. 2002. Fumonisin blunts nitric oxide-induced and nitroprusside-induced cardiomyocyte death. Nitric Oxide 7:229-235.
48. Ramer R, Walther U, Borchert P, Laufer S, Linnebacher M, Hinz B. 2013. Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib. J Lipid Res 54:3116-3129.
49. Reinehr R, Görg B, Höngen A, Häussinger D. 2004. CD95-tyrosine nitration inhibits hyperosmotic and CD95 ligand-induced CD95 activation in rat hepatocytes. J Biol Chem 279:10364-10373.
50. Roberts JL, Conley A, Booth L, Cruickshanks N, Malkin M, Kukreja RC, Grant S, Poklepovic A, Dent P. 2014. IN PRESS PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biol Ther.
51. Russwurm M, Russwurm C, Koesling D, Mergia E. 2013. NO/cGMP: The past, the present, and the future. Methods Mol Biol 1020:1-16.
52. Saba N, Hurwitz SJ, Kono S, Yang CS, Zhao Y, Chen Z, Sica GL, Muller S, Moreno-Williams R, Lewis M, Grist W, Chen AY, Moore CE, Owonikoko TK, Ramalingam SS, Beitler JJ, Nannapaneni S, Shin HJ, Grandis JR, Khuri FR, Chen ZG, Shin DM. 2013. Oct 3. [Epub ahead of print] Chemoprevention of head and neck cancer with celecoxib and erlotinib: Results of a phase 1b and pharmacokinetic study. Cancer Prev Res (Phila).
53. Sabichi A, Modiano M, Lee JJ, Peng YM, Xu MJ, Vallar H, Dalton W, Lippman S. 2003. Breast Tissue Accumulation of Retinamides in a Randomized Short-term Study of Fenretinide. Clin Cancer Res 9:2400-2405.
54. Schiffmann S, Ziebell S, Sandner J, Birod K, Deckmann K, Hartmann D, Rode S, Schmidt H, Angioni C, Geisslinger G, Grösch S. 2010. Activation of ceramide synthase 6 by celecoxib leads to a selective induction of C16:0-ceramide. Biochem Pharmacol 80:1632-1640.
55. Schiffmann S, Maier TJ, Wobst I, Janssen A, Corban-Wilhelm H, Angioni C, Geisslinger G, Grösch S. 2008. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol. 76:179-187.
56. Shen C, Yan J, Erkocak OF, Zheng XF, Chen XD. 2014. Nitric oxide inhibits autophagy via suppression of JNK in meniscal cells. Rheumatology (Oxford) 53:1022-1033.
57. Shin KO1, Park NY, Seo CH, Hong SP, Oh KW, Hong JT, Han SK, Lee YM. 2012. Inhibition of sphingolipid metabolism enhances resveratrol chemotherapy in human gastric cancer cells. Biomol Ther (Seoul) 20:470-476.
58. Soh JW, Kazi JU, Li H, Thompson WJ, Weinstein IB. 2008. Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol Carcinog 47:519-525.
59. Song J, Chen Q, Xing D. 2013. Enhanced apoptotic effects by downregulating Mcl-1: Evidence for the improvement of photodynamic therapy with Celecoxib. Exp Cell Res 319:1491-1504.
60. Swiergiel AH, Dunn AJ. 2002. Distinct roles for cyclooxygenases 1 and 2 in interleukin-1-induced behavioral changes. J Pharmacol Exp Ther 302:1031-1036.
61. Tang Y, Hamed HA, Cruickshanks N, Fisher PB, Grant S, Dent P. 2012. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Mol Pharmacol 81:527-540.
62. Tripathi DN, Chowdhury R, Trudel LJ, Tee AR, Slack RS, Walker CL, Wogan GN. 2013. Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1. Proc Natl Acad Sci USA 110:E2950-E2957.
63. Tsutsumi S, Gotoh T, Tomisato W, Mima S, Hoshino T, Hwang HJ, Takenaka H, Tsuchiya T, Mori M, Mizushima T. 2004. Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ 11:1009-1016.
64. Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, Di Mauro MG, Costa A, Marubini E, Sporn MB, De Palo G. 2006. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17:1065-1071.
65. Vosooghi M, Amini M. 2014. The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies. Expert Opin Drug Discov 9:255-267.
66. Wang H, Maurer BJ, Liu YY, Wang E, Allegood JC, Kelly S, Symolon H, Liu Y, Merrill AH, Jr, Gouazé-Andersson V, Yu JY, Giuliano AE, Cabot MC. 2008. N-(4-Hydroxyphenyl) retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. Mol Cancer Ther 7:2967-2976.
67. Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Satoh H, Terada H, Ohashi H, Hayashi H. 2002. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71:398-402.
68. Werner U, Werner D, Pahl A, Mundkowski R, Gillich M, Brune K. 2002. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed Chromatogr 16:56-60.
69. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN. 2000. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 60:6045-6051.
70. Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, Harada H, Powis G, Chen CS, Koumenis C, Grant S, Dent P. 2006. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 70:589-603.
71. Yu Y, Fan SM, Yuan SJ, Tashiro S, Onodera S, Ikejima T. 2012. Nitric oxide (•NO) generation but not ROS plays a major role in silibinin-induced autophagic and apoptotic death in human epidermoid carcinoma A431 cells. Free Radic Res 46:1346-1360.